Q-omics provides the consensus-scored SNORA71C profile across patient tissues and cancer cell-line models. SNORA71C expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SNORA71C is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, SNORA71C RNA expression shows 17,479 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where SNORA71C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA71C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA71C survival associations across molecular data types. SNORA71C RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA71C RNA expression–survival associations across cancer types. High SNORA71C expression shows unfavorable associations in KIRC, ACC, KIRP and COAD, but favorable associations in READ and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SNORA71C RNA expression.
This table summarizes SNORA71C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA71C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA71C shows higher tumor expression in COAD, HNSC, STAD, KIRC, READ and LUSC. The COAD box plot shows higher SNORA71C RNA expression in tumor versus normal tissue (log2 FC = +2.417, t-test p < 0.001).
This table shows molecular features associated with SNORA71C in patient tissues and cancer cell lines. In patient samples, SNORA71C shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
